---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014405"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T19:48:11.155379+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal

## Summary
- BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.
- Norovirus program: all 60 participants enrolled in under 2 months; topline data expected mid-2025.
- Cost reductions including workforce cuts extended cash runway into 2026; seeking additional non-dilutive funding.
- Annual meeting May 21, 2025; board seeks reverse stock split approval to avoid Nasdaq delisting; ISS and Glass Lewis recommend FOR.
- Q1 2025 earnings call scheduled for May 13, 2025; webcast at Citizens Life Sciences Conference on May 7.

## SEC filing metadata
- accession: 0001437749-25-014405
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/0001437749-25-014405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/vxrt20250503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014405
- JSON: https://secwatch.observer/filing/0001437749-25-014405.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.